{
    "clinical_study": {
        "@rank": "149747", 
        "arm_group": [
            {
                "arm_group_label": "Active, group A", 
                "arm_group_type": "Experimental", 
                "description": "Kamada-API for Inhalation, 80mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo administered by inhalation daily"
            }, 
            {
                "arm_group_label": "Active, group B", 
                "arm_group_type": "Experimental", 
                "description": "Kamada-API for Inhalation, 160mg"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate different doses of \"Kamada-API for Inhalation\" on the levels of alpha\n      1-proteinase inhibitor and other analytes in epithelial lining fluid (ELF) and serum and to\n      assess the safety of the treatment in subjects with Alpha-1 Antitrypsin Deficiency."
        }, 
        "brief_title": "Phase II, Safety and ELF Study of \"Kamada-API for Inhalation\"", 
        "condition": "Alpha-1 Antitrypsin Deficiency", 
        "condition_browse": {
            "mesh_term": "Alpha 1-Antitrypsin Deficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients between 18 and 65 years of age (inclusive).\n\n          -  Able and willing to sign informed consent.\n\n          -  Males, and non-pregnant, non-lactating females whose screening pregnancy test is\n             negative and who are using contraceptive methods deemed reliable by the investigator\n             or who are post-menopausal or surgically sterilized.\n\n          -  Diagnosis of alpha1-antitrypsin deficiency [only individuals with a ZZ or Z null\n             classification].\n\n          -  FEV1 (forced expiratory volume at one second) \u2265 50% of predicted post bronchodilator\n\n          -  No respiratory exacerbations within 6 weeks of baseline. Subjects can be re-screened\n             if exacerbations exist at the time of enrollment.\n\n          -  No signs of chronic or acute Hepatitis B, Hepatitis C or HIV infection (negative\n             serologies for HIV and viral hepatitis).  Positive serologies due to hepatitis\n             immunizations are acceptable.\n\n          -  No significant abnormalities in serum hematology, serum chemistry, serum inflammatory\n             / immunogenic markers and urinalysis.\n\n          -  No significant abnormalities in ECG.\n\n          -  Not on intravenous augmentation therapy for at least 8 weeks prior to initial dosing\n             with study drug/placebo and willing to forego intravenous augmentation therapy for\n             the duration of the study.\n\n        Exclusion Criteria:\n\n          -  Clinically significant intercurrent illnesses (except for respiratory or liver\n             disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine,\n             neurological, hematological, neoplastic, immunological, skeletal or other) that in\n             the opinion of the investigator, could interfere with the safety, compliance or other\n             aspects of this study. Patients with well-controlled, chronic diseases could possibly\n             be included after consultation with the treating physician and the sponsor.\n\n          -  History of life threatening allergy, anaphylactic reaction, or systemic response to\n             human plasma derived products.\n\n          -  History of life threatening transfusion reactions.\n\n          -  History of lung transplant.\n\n          -  Current or previous (up to 8 weeks from baseline) use of AAT augmentation therapy or\n             by any other route\n\n          -  Current use of oral or parenteral glucocorticoids in doses exceeding 10mg of\n             prednisone daily or equivalent generics (substance and dose).\n\n          -  Any lung surgery within the past two years.\n\n          -  On any thoracic surgery waiting list.\n\n          -  Active smoking during the last 12 months from screening date.\n\n          -  Pregnancy or lactation.\n\n          -  Woman of child-bearing potential not taking adequate contraception deemed reliable by\n             the investigator.\n\n          -  Presence of psychiatric/ mental disorder or any other medical disorder which might\n             impair the patient's ability to give informed consent or to comply with the\n             requirements of the study protocol.\n\n          -  Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally\n             prescribed drugs.\n\n          -  IgA (immunoglobulin A) Deficiency.\n\n          -  Inability to undergo bronchoscopy.\n\n          -  Allergy to lidocaine or any other medicines used in the bronchoscopy process\n\n          -  Exacerbation of COPD (chronic obstructive pulmonary disease) in the previous 6 weeks.\n\n          -  Participation in another clinical trial within 30 days prior to baseline visit.\n\n          -  Inability to attend scheduled clinic visits and/or comply with the study protocol.\n\n          -  Any other factor that, in the opinion of the investigator, would prevent the patient\n             form complying with the requirements of the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02001688", 
            "org_study_id": "Kamada-AAT (inhaled)-006"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active, group A", 
                "intervention_name": "Kamada-API for Inhalation, 80mg", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Active, group B", 
                "intervention_name": "Kamada-API for Inhalation, 160mg", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Joanna.Nolte@medicine.ufl.edu", 
                    "last_name": "Joanna Nolte, ARNP"
                }, 
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32610"
                    }, 
                    "name": "University of Florida, Pulmonary, Critical Care & Sleep Medicine"
                }, 
                "investigator": {
                    "last_name": "Mark Brantly, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "strangec@musc.edu", 
                    "last_name": "Charles Strange"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina, Pulmonary and Critical Care Medicine"
                }, 
                "investigator": {
                    "last_name": "Charles Strange", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "James.Stocks@uthct.edu", 
                    "last_name": "James Stocks"
                }, 
                "facility": {
                    "address": {
                        "city": "Tyler", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75708"
                    }, 
                    "name": "The University of Texas Health Science Center at Tyler Center for Clinical Research"
                }, 
                "investigator": {
                    "last_name": "James Stocks", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase II, Double-blind, Placebo-controlled Study to Explore the ELF and Plasma Concentration as Well as Safety of Inhaled Alpha-1 Antitrypsin in Alpha-1 Antitrypsin Deficiency Subjects", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Concentration of active AAT (Alpha-1 antitrypsin) in ELF", 
                "safety_issue": "No", 
                "time_frame": "3 months from dosing"
            }, 
            {
                "measure": "Concentration of antigenic AAT (Alpha-1 antitrypsin) in ELF", 
                "safety_issue": "No", 
                "time_frame": "3 months from dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02001688"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse Events, Serious Adverse Events, physical examination, vital signs", 
                "measure": "Safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "3 months and 6 months from dosing"
            }, 
            {
                "measure": "Concentration of active AAT in serum", 
                "safety_issue": "No", 
                "time_frame": "3 months from dosing"
            }, 
            {
                "description": "Cytokines and proteases", 
                "measure": "ELF inflammatory analytes", 
                "safety_issue": "No", 
                "time_frame": "3 months from dosing"
            }
        ], 
        "source": "Kamada, Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kamada, Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}